Download PDF
Facial Plast Surg 2012; 28(03): 288-293
DOI: 10.1055/s-0032-1312695
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Facial Filler and Neurotoxin Complications

Kartik Nettar
1   The Maas Clinic for Aesthetic and Facial Plastic Surgery, University of California, San Francisco, California
,
Corey Maas
1   The Maas Clinic for Aesthetic and Facial Plastic Surgery, University of California, San Francisco, California
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Botulinum neuromodulators and injectable dermal fillers have become part of the armamentarium in the treatment of facial aging. Their successful use requires a fundamental knowledge of anatomy and physiology and a sound understanding of their risks and complications. Although neuromodulators and fillers continue to demonstrate a strong record of safety, several notable risks exist.

Keywords

botulinum toxin - facial fillers - hyaluronic acid - injectables
 

  • References

  • 1 2010 Quick Facts: Cosmetic Plastic Surgery Demographic Trends. American Society of Plastic Surgery Report of the 2010 Plastic Surgery Statistics
    PubMedGoogle Scholar
  • 2 Maas CS. Botulinum neurotoxins and injectable fillers: minimally invasive management of the aging upper face. Facial Plast Surg Clin North Am 2006; 14: 241-245
    CrossrefPubMedGoogle Scholar
  • 3 MacDonald M, Spiegel J, Maas CS. Glabellar anatomy: the anatomic basis for BTox therapy. Arch Otolaryngol Head Neck Surg 1998; 124: 1315-1320
    PubMedGoogle Scholar
  • 4 Loos BM, Maas CS. Relevant anatomy for botulinum toxin facial rejuvenation. Facial Plast Surg Clin North Am 2003; 11: 439-443
    CrossrefPubMedGoogle Scholar
  • 5 Moy R, Maas C, Monheit G, Huber MB ; Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009; 11: 77-83
    CrossrefPubMedGoogle Scholar
  • 6 Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol 2005; 6: 141-150
    CrossrefPubMedGoogle Scholar
  • 7 Cho SB, Lee SJ, Kang JM, Kim YK, Ryu DJ, Lee JH. Effective treatment of a injected hyaluronic acid-induced Tyndall effect with a 1064-nm Q-switched Nd:YAG laser. Clin Exp Dermatol 2009; 34: 637-638
    CrossrefPubMedGoogle Scholar
  • 8 Weinberg MJ, Solish N. Complications of hyaluronic acid fillers. Facial Plast Surg 2009; 25: 324-328
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Bailey SH, Cohen JL, Kenkel JM. Etiology, prevention, and treatment of dermal filler complications. Aesthet Surg J 2011; 31: 110-121
    CrossrefPubMedGoogle Scholar
  • 10 Dinehart SM, Henry L. Dietary supplements: altered coagulation and effects on bruising. Dermatol Surg 2005; 31 (7 Pt 2) 819-826 ; discussion 826
    PubMedGoogle Scholar
  • 11 Seeley BM, Denton AB, Ahn MS, Maas CS. Effect of homeopathic Arnica montana on bruising in face-lifts: results of a randomized, double-blind, placebo-controlled clinical trial. Arch Facial Plast Surg 2006; 8: 54-59
    CrossrefPubMedGoogle Scholar
  • 12 Maas CS, Yu KCY, Egan K. Neuromodulators and injectable soft tissue substitutes. In: Papel I, ed. Facial Plastic and Reconstructive Surgery. New York: Thieme; 2009: 337-354
    Google Scholar
  • 13 Arduino PG, Porter SR. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral Dis 2006; 12: 254-270
    CrossrefPubMedGoogle Scholar
  • 14 Harmenberg J, Oberg B, Spruance S. Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: a literature review. Acta Derm Venereol 2010; 90: 122-130
    CrossrefPubMedGoogle Scholar